Dopamine agonists and neuroprotection in Parkinson's disease

European Journal of Neurology

Volumn 9, Issue SUPPL. 3, 2002, Pages 7-14

  Schapira, A H V ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aetiology; Dopamine agonist; Levodopa; Neuroprotection; Parkinson's disease; Pathogenesis

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROPROTECTIVE AGENT; NEUROTOXIN; OXIDOPAMINE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ROTENONE; SCAVENGER;

ANTIOXIDANT ACTIVITY; BRAIN REGION; CELL FUNCTION; DISEASE MARKER; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DYSKINESIA; ENVIRONMENTAL FACTOR; GENE MUTATION; HUMAN; IMAGING; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; ANTIOXIDANTS; BENZOTHIAZOLES; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; ENVIRONMENTAL EXPOSURE; HUMANS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; THIAZOLES;

EID: 0036460167     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.9.s3.9.x     Document Type: Review

References (76)

1. Abeliovich A, Schmitz Y, Farinas I et al. (2000). Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252.
2. Bennett J, Jr, Carvey PM, Hinds TR et al. (2001). Mechanisms of action of pramipexole. Putative neuroprotective effects. Rev Contemp Pharmaother 12:33-57.
3. Benveniste EN (1992). Inflammatory cytokines within the central nervous system: Sources, function, and mechanism of action. Am J Physiol 263:1-16.
4. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience 3:1301-1306.
5. Bolin LM, Langston JW, Di Monte D (2002). Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 83:167-175.
6. Carvey PM, Pieri S, Ling ZD (1997). Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 104:209-228.
7. Cassarino DS, Fall CP, Smith TS, Bennett JP Jr (1998). Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71:295-301.
8. Chan P, Tanner CM, Jiang X, Langston JW (1998). Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology 50:513-514.
9. Clow A, Freestone C, Lewis E, Dexter D, Sandler M, Glover V (1993). The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett 164:41-43.
10. Dexter DT, Wells FR, Agid F et al. (1987). Increased nigral iron content in post-mortem parkinsonian brain. Lancet 2:1219-1220.
11. Feany MB, Bender WW (2000). A Drosophila model of Parkinson's disease. Nature 101:451-454.
12. Finotti N, Castagna L, Moretti A, Marzatico F (2000). Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res 42:287-291.
13. Gassen M, Glinka Y, Pinchasi B, Youdim MB (1996). Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308:219-225.
14. Giasson BI, Duda JE, Murray IVJ et al. (2000). Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
15. Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC (1990). A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 27:276-228.
16. Gomez-Vargas M, Nishibayashi-Asanuma S, Asanuma M, Kondo Y, Iwata E, Ogawa N (1998). Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits peroxidation in different regions of the rat brain. Brain Res 790:202-208.
17. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002). A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52:276-284.
18. Hilker R, Klein C, Ghaemi M et al. (2001). Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 49:367-376.
19. Hirsch EC, Hunot S, Damier P, Faucheux B (1998). Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration? Ann Neurol 44:S115-S120.
20. 2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838:51-59.
21. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R (2001). An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 105:891-902.
22. Ishikawa A, Tsuji S (1996). Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 47:160-166.
23. Iwai A, Masliah E, Ypshimoto M et al. (1995). The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467-475.
24. Jenner P (1991). Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand 84:6-15.
25. Jenner P, Iravani MM, Haddon CO et al. (2002). Pramipexole protects against MPTP-induced nigral dopaminergic cell loss in primates. Neurology 58:494.
26. + toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. Neurology 56:A377-A388.
27. Kitada T, Asakawa S, Hattori N et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
28. Koller W, Vetere-Overfield B, Gray C et al. (1990). Environmental risk factors in Parkinson's disease. Neurology 40:1218-1221.
29. Kondo T, Ito T, Sugita Y (1994). Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 738:222-229.
30. Krüger R, Kuhn W, Muller T et al. (1998). Ala30Pro mutation in the gene alpha-synuclein in Parkinson's disease. Nature Genet 18:106-108.
31. Langston JW, Ballard P, Tetrud JW, Irwin I (1983). Chronic parkinsonism in humans due to a product of a meperidine-analog synthesis. Science 219:979-980.
32. Le W, Jankovic J (2001). Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Ageing 6:389-396.
33. Ling ZD, Robie HC, Tong CW, Carvey PM (1999). Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther 289:202-210.
34. Lucking CB, Durr A, Bonifati V et al. (2000). Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342:1560-1567.
35. Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, McDermott M, Kamp C, Shinaman A, Fahn S, Lang A, Weiner W, Welsh M (2002). Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 287:1653-1661.
36. Marttila RJ, Lorentz H, Rinne UK (1988). Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86:321-331.
37. Matsumine H, Saito M, Shimoda-Matsubayashi S et al. (1997). Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27 Am J Hum Genet 60:588-596.
38. McGeer PL, Itagaki S, Boyes BE, Mcgeer EG (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291.
39. Muralikrishnan D, Mohanakumar KP (1998). Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12:905-912.
40. Nishibayashi S, Asanuma M, Kohno M, Gómez-Vargas M, Ogawa N (1996). Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 67:2208-2211.
41. Ogawa N, Tanaka K, Asanuma M et al. (1994). Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro. Brain Res 657:207-213.
42. Parkinson Study Group (2000). Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 284:231-238.
43. Parsian A, Racette B, Zhang ZH et al. (1998). Mutation, sequence analysis, and association studies of alpha-synuclein in Parkinson's disease. Neurology 51:1757-1759.
44. Polymeropoulos MH, Higgins JJ, Golbe LI et al. (1996). Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274:1197-1199.
45. Polymeropoulos MH, Lavedan C, Leroy E et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
46. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000). A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484-1491.
47. Rinne UK, Bracco F, Chouza C et al. (1998). Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 55:23-30.
48. Saggu H, Cooksey J, Dexter D et al. (1989). A selective increase in particulate superoxide dismutase activity in Parkinson's substantia nigra. J Neurochem 53:692-697.
49. Saji LM, Blau AD, Volpe BT (1996). Prevention of transneuronal degeneration of neurons in the substantia nigra reticulate by ablation of the subthalamic nucleus. Exp Nuerol 141:120-129.
50. Sanchez-Ramos J, Övervuk E, Ames BN (1994). A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3:197-204.
51. Schapira AHV (1994). Evidence for mitochondrial dysfunction in Parkinson's disease: A critical appraisal. Mov Disord 9:125-138.
52. Schapira AHV (1999). Science, medicine, and the future: Parkinson's disease. BMJ 318:311-314.
53. Schapira AHV (2002b). Neuroprotection and dopamine agonists. Neurology 58:S9-S18.
54. Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989). Mitochondrial complex I deficiency in Parkinson's disease. Lancet: 1269.
55. Schapira AHV, Gu M, King DF et al. (2002a). Pramipexole protects against rotenone toxicity: Mechanisms and implications. Neurology 58:495.
56. Schapira AHV, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinsons disease. Ann Neurol in press.
57. Seidler A, Hellenbrand W, Robra BP et al. (1996). Possible environmental, occupational, and other etiologic factors for Parkinson's disease: A case-control study in Germany. Neurology 46:1275-1284.
58. Shimura H, Hattori N, Kubo S et al. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302-305.
59. Sian J, Dexter DT, Lees AJ et al. (1994). Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-355.
60. Silva MT, Schapira AHV (2001). Parkinson's disease. In: Mattson, MP, ed. Pathogenesis of Neurodegenerative Disorders. New Jersey: Humana Press Inc, pp. 53-79.
61. Sofic E, Paulus W, Jelliner K, Riederer P, Youdim MBH (1991). Selective increase of iron in substantia nigra zona compacta in parkinsonian brains. J Neurochem 56:978-982.
62. Tabrizi SJ, Orth M, Wilkinson JM et al. (2000). Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9:2683-2689.
63. Tanner C (1985). Well-water drinking and Parkinson's disease. Proceedings of the VIII International Symposium on Parkinson's Disease. New York. p. 11.
64. Tanner CM (1989). The role of environmental toxins in the etiology of Parkinson's disease. TINS 12:49-54.
65. Tipton KF, Singer T (1993). Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191-1206.
66. Ubeda A, Montesinos C, Paya M, Alcaraz MJ (1993). Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic Biol Med 15:159-167.
67. Valente EM, Brancati F, Ferraris A et al. (2002). PARK6-linked parkinsonism occurs in several European families. Ann Neurol 51:14-18.
68. Vaughan JR, Farrer MJ, Wszolek ZK et al. (1998). Sequencing of the alpha-synuclein gene in a large series of families with familial Parkinson's disease fails to reveal any further mutations. Hum Mol Genet 7:751-753.
69. Vingerhoets FJG, Snow BJ, Tetrud JJ, Langston JW, Schulzer M, Calne DB (1994). Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 36:765-770.
70. Von Voightlander PF, Fici GJ, Althaus JS (1998). Pharmacological approaches to counter the toxicity of dopa. Amino Acids 14:189-196.
71. Warner TT, Schapira AHV (1998). The role of the alpha-synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom. J Neurol Neurosurg Psychiatry 65:378-379.
72. Warner TT, Schapira AHV. Genetic and environmental factors in the aetiology of Parkinson's disease. Ann Neurol in press.
73. Whone AL, Remy P, Davis MR, Sabolek M, Nahmias C, Hamilton N, Stoessl AJ, Watts RL, Brooks DJ (2002). The REAL-PET Study: Slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology 58 (7 Suppl. 3):82-83.
74. Yoshioka M, Tanaka K, Miyazaki Ikuko Fujita N, Higashi Y, Asanuma M, Ogawa N (2002). The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neuroscience Res 43:259-267.
75. 2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 97:13 354-13 359.
76. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W (1999). Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 64:1275-1285.